Personalized CAR-T therapy for recurring brain tumor
Part of Brain & nervous system, Cancer clinical trials.
This Phase 1 study tests a personalized immune-cell treatment (CAR-T) made from your own cells to attack a marker called B7-H3 on recurring glioblastoma. It may help shrink or control the tumor, but the main goal is to check safety and how the treatment works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have glioblastoma that has come back or didn’t respond well to treatment, confirmed by recent brain scans
- You’ve had brain surgery (resection) or a biopsy at the time of diagnosis
- You are strong enough for study treatment (Karnofsky score above 60%)
- You’ve already had specific prior treatment: at least 4005 cGy radiation with chemotherapy called temozolomide
- You have not used certain anti-cancer blood-vessel medicines before (for example, bevacizumab)
- You can have repeat MRI scans (no allergy/medical issue with contrast and you have no MRI-incompatible implants)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial studies a personalized immune-cell treatment (CAR-T) for glioblastoma that has come back. It aims to shrink or control the regrowing brain tumor by using your own immune cells after processing them in a lab.
This trial tests a new CAR-T cell treatment (SNC-109) for people with glioblastoma that has come back after initial treatment. The therapy uses your own immune cells, modified in a lab, to try to attack the tumor.
This early-phase study tests a type of immune-cell treatment (CAR T cells) aimed at a target called B7-H3 in people with glioblastoma or related grade 4 brain tumors that have come back. It’s meant to see if the treatment can shrink the tumor or control the disease and to learn how safe it is.
This trial tests a new treatment called CAR-T cell therapy for people whose glioblastoma (a type of brain tumor) has come back or not responded to standard care. The treatment uses your own immune cells (T cells) that are specially modified to attack tumor cells that show a marker called CD276.
This trial tests a new kind of cell therapy called CAR-T, made from donor cells, to treat glioblastoma that has come back. The treatment targets a specific marker on the tumor (B7H3) and is injected into the brain to attack the cancer cells.
This trial tests a new treatment called TX103 CAR-T cells for people with a grade 4 glioma (like glioblastoma) that has come back or gotten worse after standard treatment. The therapy uses your own immune cells that are specially trained to attack a marker called B7-H3 found on tumor cells.
Hear when a new Glioblastoma Multiforme trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.